Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2Reportar como inadecuado

Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2 - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Disease MarkersVolume 2014 2014, Article ID 178709, 8 pages

Research ArticleInstitute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Prague 2, Czech Republic

Received 7 October 2013; Accepted 12 May 2014; Published 25 May 2014

Academic Editor: Valeria Barresi

Copyright © 2014 Pavel Majek et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The goal of this study was to explore the plasma proteome of myelodysplastic syndrome MDS patients with refractory anemia with excess blasts subtype 2 RAEB-2 in comparison to healthy controls. 20 plasma samples were separated with 2D electrophoresis and statistically processed with Progenesis SameSpots software. 47 significantly differing spots were observed, and 27 different proteins were identified by nano-LC-MS-MS. Mass spectrometry-based relative label-free quantification showed a 2-fold increase of the leucine-rich alpha-2-glycoprotein LRAG peptide levels in the RAEB-2 group. Changes in the fragments of the inter-alpha-trypsin inhibitor heavy chain H4 ITIH4 protein were observed. Western blot analysis showed no differences in albumin and ITIH4 levels, while increased expression was observed for LRAG in the RAEB-2 group. Quantification using ELISA showed decreased plasma level of alpha-2-HS glycoprotein in the RAEB-2 group. In conclusion, this is the first time that alpha-2-HS glycoprotein and LRAG were proposed as new biomarkers of RAEB-2 and advanced MDS, respectively. Alpha-2-HS glycoprotein, a protein involved in the bone marrow development and previously proposed as a MDS biomarker candidate, was significantly decreased in RAEB-2. Increased expression and changes in modifications were observed for LRAG, a protein involved in granulocytic and neutrophil differentiation, and angiogenesis.

Autor: Pavel Majek, Zuzana Riedelova-Reicheltova, Jiri Suttnar, Klara Pecankova, Jaroslav Cermak, and Jan E. Dyr



Documentos relacionados